Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 May-Jun;10(3):278-89.
doi: 10.1007/s10126-007-9062-9. Epub 2008 Jan 3.

Immunomodulatory effects of an enzymatic extract from Ecklonia cava on murine splenocytes

Affiliations

Immunomodulatory effects of an enzymatic extract from Ecklonia cava on murine splenocytes

Ginnae Ahn et al. Mar Biotechnol (NY). 2008 May-Jun.

Abstract

We investigated whether the brown seaweed Alariaceae Ecklonia cava (E. cava) has immunological effects on splenocytes in vitro. For that purpose, we prepared an enzymatic extract from E. cava (ECK) by using the protease, Kojizyme. Here, ECK administered to ICR mice dramatically enhanced the proliferation of their splenocytes and increased the number of their lymphocytes, monocytes and granulocytes. In flow cytometry assays performed to identify in detail the specific phenotypes of these proliferating cells after ECK treatment, the numbers of CD4(+) T cells, CD8(+) T cells and CD45R/B220(+) B cells increased significantly compared to those in untreated controls. In addition, the mRNA expression and production level of Th1-type cytokines, i.e., TNF-alpha and IFN-gamma, were down-regulated, whereas those of Th2-type cytokines, i.e., IL-4 and IL-10, were up-regulated by ECK. Overall, this dramatic increase in numbers of splenocytes indicated that ECK could induce these cells to proliferate and could regulate the production of Th1- as well as Th2-type cytokines in immune cells. These results suggest that ECK has the immunomodulatory ability to activate the anti-inflammatory response and/or suppress the proinflammatory response, thereby endorsing its usefulness as therapy for diseases of the immune system.

PubMed Disclaimer

References

    1. Chem Pharm Bull (Tokyo). 1989 Feb;37(2):349-53 - PubMed
    1. In Vivo. 2003 May-Jun;17(3):245-9 - PubMed
    1. Arch Neurol. 2000 Jul;57(7):1027-32 - PubMed
    1. Drug Discov Today. 2005 Apr 1;10(7):495-502 - PubMed
    1. Arch Pharm Res. 2004 Dec;27(12):1226-32 - PubMed

Publication types

MeSH terms

LinkOut - more resources